• Belgian neurotech startup ReVision Implant has raised €4M in an oversubscribed round from private investors, clearing the path to first-in-human clinical trials scheduled for Q3 2026.
• Most blindness therapies work by stimulating the retina. ReVision’s device bypasses the eye entirely, wiring directly into the brain’s visual cortex to reach patients no existing treatment can help.
• The neuroprosthetics market is valued at $13.43 billion in 2025 and is projected to reach $23.49 billion by 2030, growing at a CAGR of 11.83%, according to Mordor Intelligence.
Every blindness therapy approved today has one requirement: some part of the eye must still work. For the tens of millions of people whose retinas and optic nerves are entirely damaged, there is currently nothing.ReVision Implant is building a device for that patient group and it just raised the money to put it in a human brain for the first time.
The Leuven-based company has closed a €4 million oversubscribed round from private investors, including existing backers and new European medtech operators and business leaders. No single lead investor was named. The raise adds to ReVision’s existing public funding, which includes EU grants totalling nearly €1.5M across the EIC Pathfinder Hyperstim project and the €2.4M EIC Transition FlairVision project, bringing total publicly disclosed funding to over €5.4M. The company is also supported by Plug & Play and imec istart incubators.
